Company intelligence / Profile preview

GSK

London, England, UKsciencedirect.com ↗
Ownership
Public · GSK
Employees
~70000
Development stage
NDA
01

Overview

Global biopharma leader with commercialized products across multiple therapeutic areas and late-stage pipeline in respiratory/immunology, oncology, and infectious diseases.

Therapeutic areas
PulmonologyImmunologyDermatologyOncologyInfectious Diseases
Modalities
Small moleculesmAbsVaccinesLong-acting biologics
Industry
Pharma
02

Drug pipeline

1312 assets

Meningococcal A, C, Y and W-135 conjugate vaccine

Approved

1311 more assets in the full pipeline.

Request access →
03

Partnerships

Pfizer HIV JV
04

Financials

Market cap
$97.2B
Total revenue
$8.4B
Enterprise value
$112.3B

Beyond the preview

Go deeper on GSK.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call